Suppr超能文献

N-苄基哌啶醇衍生物作为新型 USP7 抑制剂:结构-活性关系和 X 射线晶体学研究。

N-benzylpiperidinol derivatives as novel USP7 inhibitors: Structure-activity relationships and X-ray crystallographic studies.

机构信息

Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.

State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmacy of Guangxi Normal University, Guilin, 541004, China.

出版信息

Eur J Med Chem. 2020 Aug 1;199:112279. doi: 10.1016/j.ejmech.2020.112279. Epub 2020 May 5.

Abstract

USP7 as a deubiquitinase plays important roles in regulating the stability of some oncoproteins including MDM2 and DNMT1, and thus represents a potential anticancer target. Through comparative analysis of USP7 co-crystal structures in complex with the reported piperidinol inhibitors, we noticed that the USP7 Phe409 sub-site might have good adaptability to the ligands. Based on this observation, 55 N-aromatic and N-benzyl piperidinol derivatives were designed, synthesized and biologically evaluated, among which compound L55 was identified as a highly selective and potent USP7 inhibitor (IC = 40.8 nM, K = 78.3 nM). X-ray crystallographic studies revealed that L55 bound to USP7 with a new pose that was very different from the previously reported inhibitors. The results of cellular assays showed that L55 had strong antitumor activity against LNCaP (IC = 29.6 nM) and RS4; 11 (IC = 41.6 nM) cells, probably through inducing cell death and restricting G0/G1 and S phases. Moreover, L55 dose-dependently reduced the protein levels of MDM2 and DNMT1 and increased the protein levels of p53 and p21. These findings could have valuable implications for designing novel structural classes of USP7 inhibitors.

摘要

USP7 作为一种去泛素化酶,在调节某些癌蛋白(包括 MDM2 和 DNMT1)的稳定性方面发挥着重要作用,因此它代表了一个潜在的抗癌靶点。通过对与报道的哌啶醇抑制剂复合的 USP7 共晶结构进行比较分析,我们注意到 USP7 的 Phe409 亚位点可能对配体具有良好的适应性。基于这一观察结果,设计、合成并对 55 个 N-芳基和 N-苄基哌啶醇衍生物进行了生物学评估,其中化合物 L55 被鉴定为一种高选择性和强效的 USP7 抑制剂(IC = 40.8 nM,K = 78.3 nM)。X 射线晶体学研究表明,L55 与 USP7 结合的新构象与先前报道的抑制剂非常不同。细胞测定结果表明,L55 对 LNCaP(IC = 29.6 nM)和 RS4;11(IC = 41.6 nM)细胞具有很强的抗肿瘤活性,可能通过诱导细胞死亡和限制 G0/G1 和 S 期。此外,L55 剂量依赖性地降低了 MDM2 和 DNMT1 的蛋白水平,并增加了 p53 和 p21 的蛋白水平。这些发现可能对设计新型 USP7 抑制剂结构类具有重要意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验